Market Overview

UPDATE: Burril Initiates Sarepta Therapeutics at Market Outperform on Eteplirsen Potential

16 Biotech Catalysts SunTrust Is Tracking
CNBC's Stock Pops & Drops From April 1: GoPro, Michael Kors, Delta, Sarepta
Santhera: the only DMD drug with a successful phase III study (Seeking Alpha)

Burril initiated coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Market Outperform rating and a $54 price target.

Burril commented, "Sarepta is currently in clinical trials evaluating Eteplirsen, a novel RNA splicing modulator poised to correct genetic mutations which result in a dysfunctional protein and cause diseases of large unmet need. To date, the company has demonstrated both safety and preliminary efficacy in Phase 1 and Phase 2 trials with patients amenable to Exon 51 therapy in Duchenne's Muscular Dystrophy (DMD). Given the final encouraging results from the 201/202 Phase 2 study, we believe shares are poised to move higher. If successful, we believe Sarepta's directed alternative splicing technology has the potential to revitalize the RNA therapeutics space and address multiple multi-billion dollar orphan disease markets."

Sarepta Therapeutics closed at $29.35 on Friday.

Latest Ratings for SRPT

Feb 2015Cowen & CompanyDowngradesOutperformMarket Perform
Feb 2015Bank of AmericaUpgradesBuy
Jan 2015WedbushInitiates Coverage onNeutral

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: BurrilAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (SRPT)

Around the Web, We're Loving...